Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
Eyedrops From Major Brands May Cause Infection, F.D.A. Saysnews2023-10-29T23:47:48+00:00October 29th, 2023|The New York Times|
Biden’s Aid, and Pointed Advice, to Israelnews2023-10-19T17:41:12+00:00October 19th, 2023|The New York Times|
Family Dollar Recalls Hundreds of Products Sold in 23 Statesnews2023-10-14T16:06:29+00:00October 14th, 2023|The New York Times|
Do Early R.S.V. Vaccine Trials Have a Henrietta Lacks Story?news2023-10-11T23:00:12+00:00October 11th, 2023|The New York Times|
FDA Issues Warning Over Misuse of Ketamine Therapynews2023-10-11T20:50:31+00:00October 11th, 2023|The New York Times|
For the F.D.A., Cold Medicine That Doesn’t Work Is Just the Tip of the Icebergnews2023-09-29T09:01:58+00:00September 29th, 2023|The New York Times|
Why It Took So Long for the FDA to Tackle a Cold Medicinenews2023-09-15T22:52:53+00:00September 15th, 2023|The New York Times|
Nuevas vacunas contra la covid en EE. UU.: lo que hay que sabernews2023-09-13T04:05:02+00:00September 13th, 2023|The New York Times|
